Malawi needs donor support to maintain HIV/AIDS treatment program

NewsGuard 100/100 Score

In the last of a series of posts on the U.K. Department for International Development's (DfID) blog examining the department's work in Malawi, Neil Squires, DfID head of profession for health, looks at the sustainability of the country's HIV/AIDS program. "Malawi's success in increasing access to antiretroviral drugs for HIV is highly dependent on donor funding for medicines," he writes, adding, "Malawi has to actively consider its resource allocation in order to maximize the benefits and the health gained from the limited resources available." He notes a report commissioned by UNAIDS on Malawi concluded that "unless Malawi can reduce the incidence of new infections, the scale up in access to antiretroviral drugs will not be sustainable in the medium to long term." He concludes, "This is an important issue for the Government of Malawi, but also for the key donors who have supported the massive scale up in access to drugs, particularly the Global Fund. Malawi will need to maintain high levels of funding from the Global Fund if it is to maintain its supply of antiretroviral drugs" (10/23).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough study offers hope for an effective HIV cure